Allogene Therapeutics
Maria Elena Hochkoeppler is a seasoned professional in stability and quality control, currently serving as the Senior Manager of Stability, Standards, and Controls Program at Allogene Therapeutics since March 2019. Prior experience includes a tenure as Senior Manager of Stability Commercial QC at Intarcia Therapeutics, Inc. from July 2017 to March 2019, and an extensive role at Novartis from January 2009 to July 2017, where positions ranged from Manager/Compliance and Operations to Senior Scientist and Scientist. Additionally, Maria Elena worked as a Senior Research Associate at Nektar Therapeutics from June 2006 to December 2008. Educationally, Maria Elena holds a Bachelor of Science degree in Biochemistry from California Polytechnic State University-San Luis Obispo.
This person is not in any teams
This person is not in any offices
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.